FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...

Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, ...

– Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – FOSTER CITY, CA, USA I February 20, 2025 I Gilead ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).

Gilead Sciences's GILD short percent of float has risen 6.47% since its last report. The company recently reported that it ...

In high finance, the key ratio used to measure how well a company converts reported profits ... Over the twelve months to December 2024, Gilead Sciences recorded an accrual ratio of -0.27.

In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector. Net Margin: Gilead Sciences's net margin is below ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Gilead Sciences ... includes roles at Computer Sciences Corporation (NYSE:DXC), Caesars (NASDAQ:CZR) Entertainment Corporation, and Eastman Kodak Company. Wilfong is a certified public accountant ...